Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01707745
NCT01707745
Unknown
Not Applicable

Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.

Sivakami A Pai1 site in 1 country50 target enrollmentJanuary 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsStage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.
Sponsor
Sivakami A Pai
Enrollment
50
Locations
1
Primary Endpoint
Regression Of ROP
Last Updated
13 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

Prospective study to evaluate the efficacy and safety of intravitreal bevacizumab In retinopathy of prematurity (ROP).

Bevacizumab 0.75 mg in 0.03 ml was given to stage 2+ or stage 3+ ROP in Zone I or Zone II.

Registry
clinicaltrials.gov
Start Date
January 2010
End Date
December 2012
Last Updated
13 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Sivakami A Pai
Responsible Party
Sponsor Investigator
Principal Investigator

Sivakami A Pai

Doctor

Dubai Health Authority

Eligibility Criteria

Inclusion Criteria

  • •stage 2+ or stage 3+ Retinopathy of prematurity in Zone I or Zone II.
  • •Informed written consent by parents or guardian.

Exclusion Criteria

  • •Refusal to give consent Critically ill neonates.

Outcomes

Primary Outcomes

Regression Of ROP

Time Frame: Minimum 6 months follow up after intravitreal Avastin

Secondary Outcomes

  • Recurrence of ROP(minimum 6 months of follow up.)

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Study for efficacy and safety of intravitreal injection of bevacizumab (Avastin)diabetic retinopathy central retinal vein occulusion, neovascular glaucoma
JPRN-UMIN000012248ational Center for Global Health and Medicine, Kohnodai Hospital20
Completed
Phase 4
Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic RetinopathyProliferative Diabetic Retinopathy
NCT01025934University of Campania "Luigi Vanvitelli"
Completed
Phase 4
Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic RetinopathyProliferative Diabetic RetinopathyDiabetic Traction Retinal DetachmentVitreous Hemorrhage
NCT01854593Nihon University69
Unknown
Phase 3
Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)Diabetic Retinopathy
NCT00370721Shahid Beheshti University of Medical Sciences
Unknown
Phase 2
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of PrematurityRetinopathy of Prematurity
NCT00622726The University of Texas Health Science Center, Houston150